(S)-4-[[[1-(4-fluorophenyl)-3-(1-methylethyl)-1H-indol-2-yl]-ethynyl]hydroxyphosphinyl]-3-hydroxybutanoic acid | 119901-68-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: (S)-4-[[[1-(4-fluorophenyl)-3-(1-methylethyl)-1H-indol-2-yl]-ethynyl]hydroxyphosphinyl]-3-hydroxybutanoic acid
• 英文别名: Butanoic acid, 4-(((1-(4-fluorophenyl)-3-(1-methylethyl)-1H-indol-2-yl)ethynyl)hydroxyphosphinyl)-3-hydroxy-, (3S)-；(3S)-4-[2-[1-(4-fluorophenyl)-3-propan-2-ylindol-2-yl]ethynyl-hydroxyphosphoryl]-3-hydroxybutanoic acid
• CAS: 119901-68-7
• 化学式: C₂₃H₂₃FNO₅P
• 分子量: 443.411
• InChiKey: DVRZSYZTEHXMHH-SFHVURJKSA-N

物化性质

• 沸点：
  609.5±65.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  99.8
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Use of an HMG CoA reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease
  申请人：E.R. Squibb & Sons, Inc.

  公开号：EP0401705A2

  公开（公告）日：1990-12-12

  A use of a pharmaceutical composition is provided for treating peripheral atherosclerotic disease (arte­riosclerosis obliterans) and/or intermittent claudication containing an HMG CoA reductase inhibitor alone and/or inhibitor of the enzyme squalene synthetase and optionally a pharmaceutical which reduces serum cholesterol by a mechanism other than inhibiting production of the enzyme HMG CoA reductase or the enzyme squalene synthetase, for example, probucol or gemfibrozil.

  提供了一种用于治疗外周动脉粥样硬化性疾病（动脉硬化闭塞症）和/或间歇性跛行的药物组合物的用途，该组合物包含单独的 HMG CoA 还原酶抑制剂和/或角鲨烯合成酶抑制剂，以及可选的通过抑制 HMG CoA 还原酶或角鲨烯合成酶的产生以外的机制降低血清胆固醇的药物，例如普鲁醇或吉非罗齐。
• Method for preventing a second heart attack employing and HMG CoA reductase inhibitor
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0461548A2

  公开（公告）日：1991-12-18

  A method is provided for preventing or reducing the risk of a second heart attack by administering an HMG CoA reductase inhibitor such as pravastatin, alone or in combination with an ACE inhibitor.

  提供了一种通过单独或与 ACE 抑制剂联合使用 HMG CoA 还原酶抑制剂（如普伐他汀）来预防或降低第二次心脏病发作风险的方法。
• Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0482498A2

  公开（公告）日：1992-04-29

  A method is provided for preventing diabetes and preventing complications resulting from diabetes by administering to a diabetic patient a cholesterol lowering drug, such as pravastatin, alone or in combination with an ACE inhibitor, such as captopril, zofenopril, ceronapril, fosinopril, enalapril or lisinopril.

  提供了一种预防糖尿病和预防糖尿病并发症的方法，给糖尿病患者单独或与 ACE 抑制剂（如卡托普利、佐芬普利、塞罗那普利、福辛普利、依那普利或赖西诺普利）联合使用降低胆固醇的药物，如普伐他汀。
• Use of ACE inhibitors for lowering serum cholesterol
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0508665A2

  公开（公告）日：1992-10-14

  A method is provided for lowering serum cholesterol and thereby inhibiting fatty streak lesions of atherosclerosis by administering to a patient a phosphorus-containing ACE inhibitor, such as fosinopril or ceronapril, alone or in combination with a cholesterol lowering drug, such as pravastatin.

  提供了一种降低血清胆固醇从而抑制动脉粥样硬化脂肪条纹病变的方法，该方法是给患者单独使用或与降低胆固醇的药物（如普伐他汀）联合使用含磷 ACE 抑制剂，如福辛普利或塞洛那普利。
• Use of a HMG CoA reductase inhibitor to prevent a second heart attack
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0738512A1

  公开（公告）日：1996-10-23

  A method is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an HMG CoA reductase inhibitor such as pravastatin, alone or in combination with an ACE inhibitor.

  提供了一种方法，通过单独或与 ACE 抑制剂联合使用 HMG CoA 还原酶抑制剂（如普伐他汀），预防或降低血清胆固醇水平基本正常的患者第二次心脏病发作的风险。